|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||80.85 - 81.54|
|52 Week Range||69.35 - 89.72|
|PE Ratio (TTM)||22.35|
|Forward Dividend & Yield||1.84 (2.27%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval. Commissioner Scott Gottlieb announced the proposal in a blog posted on the FDA's website. If implemented, it could save device companies millions of dollars in product testing and shave years off development times.
There are never any guarantees that past performance will equal future performance, but we are now just five weeks into the seasonally favorable November-April time of the year.
In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.
Runaway success for this pioneer of robot-assisted surgery has inspired a slew of competitors to enter the arena.
Medtronic provides solutions to hospitals, which translate the clinical value to economic value for these hospitals.
Medtronic's TYRX-based infection reduction program is accelerating at a strong pace. The number of accounts under this contract tripled to around 900 hospitals in fiscal 2Q18.
In fiscal 2Q18, Medtronic's Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
Medtronic's CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.
BD (BDX) has always focused on providing innovative products and solutions to its customers. The company makes considerable R&D (research and development) investments. In fiscal 4Q17, BD invested approximately ...
Boston Scientific dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge.
As of November 23, 2017, the analysts' consensus target price for MDT for the next 12 months is $90.11, which represents an approximately 9.4% return on the basis of the stock's closing price of $82.3 ...
Medtronic and the Internal Revenue Service will head back to court next year over a high-stakes tax battle regarding how the med-tech giant accounts for business at its Puerto Rico manufacturing facilities. The Star Tribune has details of the complex and long-running case in which the IRS argues that Medtronic is underreporting its taxable income by $1.4 billion by failing to account for trade secrets used by its Puerto Rico factories.
During the company's 2Q18 earnings release on November 21, 2017, Medtronic (MDT) provided guidance for the full fiscal 2018.
Medtronic (MDT) maintained its fiscal 2018 guidance during the company’s 2Q18 earnings release on November 21, 2017, despite the adverse impact from natural disasters on the company’s performance during ...
Medtronic’s 2Q18 results surpassed analysts’ estimates despite a number of factors that hurt the company’s performance.
Medtronic released its 2Q18 earnings results on November 21, 2017. The company registered sales of around $7.1 billion, representing a YoY (year-over-year) decline of around 4%.